Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.
There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.
The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.
Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.
Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.
Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.
Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.
Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.
Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.
